iShares Russell 2000 ETF vs 10X Genomics Inc — how do they compare? iShares Russell 2000 ETF trades at $278.54 (market cap $77.70B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: iShares Russell 2000 ETF is far larger — about 7.7× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares Russell 2000 ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and 10X Genomics Inc for 92 Days on average.
| IWM | TXG | |
|---|---|---|
Market Cap | $77.70B | $10.07B |
Volume | 35,598,983 | 5,657,286 |
52-Week High | $305.06 | $97.74 |
52-Week Low | $229.13 | $11.48 |
Typical Hold Time | 83 Days | 92 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.72, down 1.27% amid broader small-cap weakness. Technical indicators show a bearish trend with resistance at $278 and support at $275. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.
The outlook remains cautious as rising interest rates pressure small-cap valuations. Opportunities exist for long-term investors seeking diversification from tech-heavy large caps, but near-term risks include economic sensitivity and narrow market breadth. The bearish technical setup suggests further downside potential unless macroeconomic conditions improve.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →